Patents by Inventor Travis Wilson

Travis Wilson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide therapeutics and methods for using same
    Patent number: 10293020
    Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of an MPP, and/or naturally or artificially occurring variants or analogs of an MPP, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide such as D-Arg-2?6?-Dmt-Lys-Phe-NH2).
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: May 21, 2019
    Assignee: STEALTH BIOTHERAPEUTICS CORP.
    Inventor: D. Travis Wilson
  • Methods and compositions for increasing the dose of a chemotherapeutic agent
    Patent number: 10279008
    Abstract: The disclosure relates to methods for treating a subject suffering from hyperalgesia caused by drug-induced neuropathy by administering to the subject an effective amount of an aromatic-cationic peptide. The disclosure also relates to methods for protecting a subject from hyperalgesia caused by drug-induced neuropathy by administering an effective amount of an aromatic-cationic peptide to a subject at risk for developing the condition.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: May 7, 2019
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • Pharmaceutically relevant aromatic-cationic peptides
    Patent number: 10221213
    Abstract: The present technology provides peptides, methods of generating the peptides, and pharmaceutically acceptable salts of the peptides. In some embodiments, the peptide is D-Arg-2?6?-Dmt-Lys-Phe-NH2.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: March 5, 2019
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • Methods for treatment of atherosclerosis
    Patent number: 10201585
    Abstract: Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and, in some applications, a second active agent, to subjects in need thereof. The present technology relates to the treatment or prevention of atherosclerosis in mammals through the administration of a therapeutically effective amount of aromatic cationic peptides and, in some embodiments, a second active agent.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: February 12, 2019
    Assignee: Stealth Biotherapeutics Corp
    Inventors: D. Travis Wilson, Mark Bamberger, Brian Blakey
  • Methods for treatment of atherosclerosis
    Patent number: 10188693
    Abstract: Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and in some applications, a second active agent chemically linked to the peptide, to subjects in need thereof.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: January 29, 2019
    Assignee: Stealth Biotherapeutics Corp
    Inventors: D. Travis Wilson, Mark Bamberger, Brian Blakey, Marc W. Andersen
  • METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
    Publication number: 20190022167
    Abstract: The disclosure provides methods of preventing or treating DMD in a mammalian subject, reducing risk factors associated with DMD, and/or reducing the likelihood or severity of DMD. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 24, 2019
    Inventor: D. Travis Wilson
  • METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF PULMONARY ARTERIAL HYPERTENSION
    Publication number: 20190022165
    Abstract: The disclosure provides methods of preventing or treating pulmonary arterial hypertension (PAH) in a mammalian subject, reducing risk factors associated with PAH, and/or reducing the likelihood or severity of PAH. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.
    Type: Application
    Filed: March 2, 2017
    Publication date: January 24, 2019
    Inventor: D. Travis WILSON
  • THERAPEUTIC COMPOSITIONS INCLUDING PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES AND USES THEREOF
    Publication number: 20190023738
    Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of phenazine-3-one and/or phenothiazine-3-one derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to phenazine-3-one or phenothiazine-3-one derivatives and uses of the same. In some embodiments, the aromatic-cationic peptide comprises D-Arg-2?6?-Dmt-Lys-Phe-NH2.
    Type: Application
    Filed: February 14, 2018
    Publication date: January 24, 2019
    Inventor: D. Travis Wilson
  • METHODS FOR THE REGULATION OF MATRIX METALLOPROTEINASE EXPRESSION
    Publication number: 20190000915
    Abstract: The disclosure provides methods of reducing MMP-9 expression and/or MMP-9 activity in a mammalian subject. The disclosure also provides methods of increasing TIMP-1 expression and/or TIMP-1 activity in a mammalian subject. The methods comprise administering a therapeutically effective amount of an aromatic-cationic peptide to a subject in need thereof.
    Type: Application
    Filed: January 29, 2018
    Publication date: January 3, 2019
    Inventors: D. Travis Wilson, Robert A. Kloner
  • METHODS AND COMPOSITIONS FOR REGULATING SRCA2A EXPRESSION LEVELS IN MYOCARDIAL INFARCTION
    Publication number: 20180360906
    Abstract: The disclosure provides methods and compositions for increasing SERCA2a expression levels in a mammalian subject in need thereof. The methods comprise administering to the subject a therapeutic amount of an aromatic-cationic peptide to subjects in need thereof. In some embodiments, the aromatic-cationic peptide is D-Arg-2?6?-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof such as acetate or trifluoroacetate salt. In some embodiments, the subject has suffered a myocardial infarction.
    Type: Application
    Filed: January 17, 2018
    Publication date: December 20, 2018
    Inventors: D. Travis WILSON, Robert A. KLONER
  • AROMATIC-CATIONIC PEPTIDES AND USES OF SAME
    Publication number: 20180362579
    Abstract: The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.
    Type: Application
    Filed: January 9, 2018
    Publication date: December 20, 2018
    Inventors: D. Travis WILSON, Marc W. ANDERSEN, Elizabeth MEAD
  • THERAPEUTIC COMPOSITIONS INCLUDING GRAMICIDIN S PEPTIDYL CONJUGATES OR IMIDAZOLE-SUBSTITUTED FATTY ACIDS, VARIANTS THEREOF AND USES THEREOF
    Publication number: 20180354991
    Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of Gramicidin S peptidyl conjugates (and/or derivatives, analogues, or pharmaceutically acceptable salts thereof), or imidazole-substituted fatty acids (and/or derivatives, analogues, or pharmaceutically acceptable salts thereof), alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to imidazole-substituted fatty acids or Gramicidin S peptidyl conjugates of the present technology and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2?,6?-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2?,6?-Dmt-Lys-Phe-NH2.
    Type: Application
    Filed: December 21, 2017
    Publication date: December 13, 2018
    Inventor: D. Travis Wilson
  • METHODS FOR TREATMENT OF ATHEROSCLEROSIS
    Publication number: 20180344797
    Abstract: Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and, in some applications, a second active agent, to subjects in need thereof. The present technology relates to the treatment or prevention of atherosclerosis in mammals through the administration of a therapeutically effective amount of aromatic cationic peptides and, in some embodiments, a second active agent.
    Type: Application
    Filed: December 20, 2017
    Publication date: December 6, 2018
    Inventors: D. Travis Wilson, Mark Bamberger, Brian Blakey
  • PEPTIDE THERAPEUTICS AND METHODS FOR USING SAME
    Publication number: 20180344814
    Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of GLP-1, and/or naturally or artificially occurring variants or analogues of GLP-1, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide such as D-Arg-2?6?-Dmt-Lys-Phe-NH2).
    Type: Application
    Filed: December 21, 2017
    Publication date: December 6, 2018
    Inventor: D. Travis Wilson
  • METHODS FOR TREATMENT OF ATHEROSCLEROSIS
    Publication number: 20180339012
    Abstract: Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and in some applications, a second active agent chemically linked to the peptide, to subjects in need thereof.
    Type: Application
    Filed: December 20, 2017
    Publication date: November 29, 2018
    Inventors: D. Travis Wilson, Mark Bamberger, Brian Blakey, Marc W. Andersen
  • AROMATIC-CATIONIC PEPTIDES AND METHODS FOR USING SAME
    Publication number: 20180327450
    Abstract: The present disclosure provides methods of preventing or treating renal ischemia-reperfusion injury in a mammalian subject and methods for chronic treatment of ARVD, including administering an effective amount of an aromatic-cationic peptide to a subject in need thereof. The methods include administering aromatic-cationic peptides to prevent or treat renal injury during the treatment of renal artery stenosis. The methods include administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Application
    Filed: December 13, 2017
    Publication date: November 15, 2018
    Inventors: D. Travis Wilson, Lilach O. Lerman, Stephen C. Textor
  • METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS
    Publication number: 20180296630
    Abstract: The disclosure provides methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. More specifically, the disclosure provides a composition for preventing, treating, or ameliorating the symptoms of diabetic macular edema in a mammalian subject in need thereof, comprising: a therapeutically effective amount of a peptide D-Arg-2?6?-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 29, 2017
    Publication date: October 18, 2018
    Inventors: D. Travis Wilson, K. George Mooney, Peter J. Oates
  • METHODS FOR THE PREVENTION OR TREATMENT OF VESSEL OCCLUSION INJURY
    Publication number: 20180228864
    Abstract: This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof, wherein the peptide is D-Arg-2 6-Dmt-Lys-Phe-NH2 (SS-31).
    Type: Application
    Filed: September 27, 2017
    Publication date: August 16, 2018
    Inventors: Kenneth Borow, D. Travis Wilson
  • Methods and compositions for detecting and diagnosing diseases and conditions
    Patent number: 10047395
    Abstract: The disclosure provides methods for detecting and diagnosing diseases and conditions associated with defects in cardiolipin remodeling. In some embodiments, the present technology relates to methods for detecting the presence or amount of cardiolipin isoforms and/or the presence or amount of enzymes involved in cardiolipin remodeling.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: August 14, 2018
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF FRIEDREICH'S ATAXIA
    Publication number: 20180207225
    Abstract: The disclosure provides methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia, and/or reducing the likelihood or severity of Friedreich's ataxia. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to e.g., reduce oxidative stress, increase mitochondrial metabolism, or a combination thereof.
    Type: Application
    Filed: September 7, 2017
    Publication date: July 26, 2018
    Inventor: D. Travis Wilson